Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket studyLingfang Xia, Xiaohua Wu, Jin Peng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 39
Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).Yun Zhang, Quanren Wang, Guoliang Shao et al.|Journal of Clinical Oncology|2021Cited by 10
Efficacy and safety benefits of <scp>HR17031</scp> , a fixed‐ratio combination of <scp>INS068</scp> and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open‐label, randomised, parallel three‐arm, treat‐to‐target trialLinong Ji, Zi Ye, Xiang Lin et al.|Diabetes Obesity and Metabolism|2025Cited by 1